OptumRx, 2300 Main St., Irvine, CA 92614.
J Manag Care Spec Pharm. 2015 Sep;21(9):803-10. doi: 10.18553/jmcp.2015.21.9.803.
Osteoporosis-related fractures are a considerable economic burden on the U.S. health care system. Since 2008, the Centers for Medicare Medicaid Services have adopted a Medicare Part C Five-Star Quality Rating measure to ensure that a woman's previously unaddressed osteoporosis is managed appropriately after a fracture. Despite the effort to improve this gap in care, the 2013 CMS plan ratings fact sheet reported an average star rating of 1.4 stars for the osteoporosis measure, the lowest score for any measure across all health plans.
To evaluate the impact of conducting a pharmacist-led, telephone outreach program to members or their providers to improve osteoporosis management in elderly women after experiencing fractures.
This was a prospective, randomized study to evaluate the effectiveness of 3 different intervention strategies within a nationwide managed care population. Women aged 66 years and older who experienced a new bone fracture between January 1, 2012-August 31, 2012, were identified through medical claims. Women who were treated with an osteoporosis medication or received a bone mineral density (BMD) test within a year of their fractures were excluded. Study patients were randomized into 3 intervention cohorts: (1) baseline intervention consisting of member educational mailing and provider educational mail or fax notification; (2) baseline intervention plus a live outbound intervention call to members by a pharmacist; and (3) baseline intervention plus a pharmacist call to members' providers to recommend starting osteoporosis therapy and/or a bone mineral density (BMD) test. An intent-to-treat and per protocol analyses were employed, and appropriate osteoporosis management (initiation of osteoporosis therapy and/or BMD testing) 120 days after the baseline intervention and 180 days after a fracture were measured.
The study identified 6,591 members who were equally randomized into 3 cohorts. The baseline demographics in each cohort were similar. Results of the intent-to-treat analysis showed more members in cohort 3 receiving appropriate osteoporosis management (13.0%) compared with those in cohort 2 (10.3%, P less than 0.005) or compared with those in cohort 1 (9.1%, P less than 0.001). No difference was detected between those receiving additional member calls (cohort 2) and those receiving only the baseline intervention (cohort 1). Similar results were observed utilizing the 180 days after fracture time frame.
The effectiveness of a pharmacist-led telephone intervention directed at providers or members was examined in this randomized study. Pharmacist calls to members did not improve osteoporosis management over member and provider mail and fax notifications. Greater impact was demonstrated by performing a pharmacist call intervention with providers rather than with members.
骨质疏松性骨折给美国医疗保健系统带来了相当大的经济负担。自 2008 年以来,医疗保险和医疗补助服务中心采用了医疗保险 C 部分五星级质量评级措施,以确保女性在骨折后得到适当的治疗。尽管努力改善这一护理差距,但 2013 年 CMS 计划评级情况说明书报告称,骨质疏松症措施的平均星级评分为 1.4 星,是所有医疗计划中所有措施中得分最低的。
评估开展药剂师主导的电话外展计划对经历骨折的老年女性骨质疏松症管理的影响。
这是一项前瞻性、随机研究,评估了全国范围内管理式医疗人群中 3 种不同干预策略的有效性。通过医疗索赔确定 2012 年 1 月 1 日至 2012 年 8 月 31 日期间发生新骨折的 66 岁及以上女性。在骨折一年内接受骨质疏松症药物治疗或接受骨密度(BMD)检测的女性被排除在外。研究患者被随机分为 3 个干预组:(1)基线干预,包括成员教育邮寄和提供者教育邮件或传真通知;(2)基线干预加药剂师对成员的现场外展电话;(3)基线干预加药剂师致电成员的提供者,建议开始骨质疏松症治疗和/或进行骨密度(BMD)测试。采用意向治疗和方案分析,并在基线干预后 120 天和骨折后 180 天测量适当的骨质疏松症管理(开始骨质疏松症治疗和/或 BMD 测试)。
该研究确定了 6591 名成员,他们被平均随机分配到 3 个队列中。每个队列的基线人口统计学特征相似。意向治疗分析结果显示,第 3 组中有更多的成员接受了适当的骨质疏松症管理(13.0%),而第 2 组(10.3%,P<0.005)或第 1 组(9.1%,P<0.001)。与仅接受基线干预的第 1 组(9.1%,P<0.001)相比,接受额外成员电话的成员(第 2 组)之间没有差异。在骨折后 180 天的时间框架内观察到了类似的结果。
在这项随机研究中,对药剂师主导的针对提供者或成员的电话干预的有效性进行了检查。药剂师致电成员并未改善成员和提供者邮件和传真通知的骨质疏松症管理。与针对成员的干预相比,针对提供者的药剂师电话干预产生了更大的影响。